Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial
European urology（2022）
关键词
AKT inhibitor,Capivasertib,Docetaxel,Metastatic castration-resistant,prostate cancer,PI3K,AKT,PTEN pathway,Phase 2 trial
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要